Corporate / M&A
Corporate M&A
In what will possibly have been its last quarter of existing as a single firm, Amarchand Mangaldas again acted on the most valuable M&A deals though AZB & Partners emerged as the firm with the largest number of recorded transactions.
Corporate M&A
The firm of former AZB & Partners CEO Abhijit Joshi, Veritas Legal, has advised German specialty chemicals company Evonik on its acquisition of Mumbai-based catalyst supplier Monarch Catalyst, which was advised by J Sagar Associates (JSA) partner Sandeep Mehta.
The value of the purchase of the family owned company founded in 1973 was not disclosed. It is expected to close in the first half of 2015, reported Mint.
Corporate M&A
J Sagar Associates (JSA) advised Reliance Infra on its Rs 819 crore ($130m) acquisition of 18 per cent stake in Pipavav Defence and Offshore Engineering which was advised by K Law and Crawford Bayley.
Corporate M&A
Induslaw represented Olacabs, which must fast be turning into one of its most high-profile and valuable clients, in a $200m takeover of TaxiForSure.
Corporate M&A
Amarchand maintained its standing as India’s clear M&A leader topping the annual chart for the third year in a row.
Corporate M&A
Bharucha & Partners advised social media giant Twitter on its first acquisition in India, in its $30m buy of missed-call marketing platform ZipDial Mobile Solutions, which was advised by AZB & Partners.
Corporate M&A
Amarchand Mangaldas and K&L Gates advised US-based Par Pharmaceuticals and its wholly-owned Indian subsidiary Par Formulations on its acquisition of Chennai-based Ethics Biolabs, which was advised by HSB Partners.
Amarchand Delhi partners Amit Kumar and Arvind Sharma, principal associate designate Janani Sekhar and senior associate Ananda Malhotra acted for Par Pharmaceuticals.
HSB partners TK Bhaskar and Varun Sriram with associate Anantha Krishnan Iyer acted for Ethics Biolabs and its selling promoters. Ethics conducts “bioavailability, bioequivalence, pharmacokinetic and clinical end point studies for pharmaceutical and biotechnology companies”, started an Amarchand press release. The value of the deal, which closed on 14 January, was confidential.